Back

Featured Topics

Behind The Science
Breast Cancer
Cancer Immunotherapy
Hematology
Lung Cancer
Manufacturing
Multiple Sclerosis
Oncology
Ophthalmology
Partnering
Respiratory Health
Rheumatology
About Us Contact Us Leadership Awards & Recognition Investors Suppliers Compliance
  • Share
  • Twitter
  • Facebook
  • LinkedIn
  • Email
  • Heart
  • Twitter
  • Facebook
  • LinkedIn
  • Email

Pioneering Partnerships


Read More Stories
Oct 17, 2013

James Sabry, M.D., Ph.D.

Senior Vice President and Global Head of Genentech Partnering


In 1972 at a scientific meeting in Hawaii, Herb Boyer and Stanley Cohen met to discuss how their labs could collaborate. Herb’s laboratory at UCSF was studying how certain enzymes cut DNA and Stanley Cohen’s lab discovered how to get bacteria to take up DNA.

Their collaboration was close, and they shuttled experiments back and forth between the two campuses. This partnership ultimately played a key role is discovering recombinant DNA (rDNA) technology and founding Genentech. Read Biotech Basics to learn more about their first meeting and rDNA technology.


Good science doesn’t happen in a vacuum and curing diseases is going to require doctors, scientists and companies coming together.


Genentech pioneered rDNA technology, which came from an academic collaboration, to develop recombinant human insulin. Back then Genentech was a small fledgling company, so we partnered with Eli Lilly. We knew that Lilly would be able to test and market the medicine much faster than if we did it alone.

Recombinant human insulin became the first medicine to approved by the FDA to be made from rDNA technology. In the end, it was that first partnership that gave us the ability to start developing as a company.

Seeking good science

Today, our position is very different than it was 40 years ago. And while we’re extremely proud of our research and development programs, we recognize that we do not have a monopoly on ingenuity. Discovery happens every day, in academic labs, small biotech companies and even large pharmaceutical companies. We seek those discoveries that complement the work that we are doing here.

Outside Collaboration
is involved in more than
50%
of medicines in development
Scientists or Doctors
make up
70%
of people in business development

Consider antibody-drug conjugates. This type of medicine is designed to deliver chemotherapy directly to a cell that carries specific surface markers by linking it to an antibody. Our partner company was small, but expert in the complicated chemistry behind the linker technology.

They performed the early original and elegant work on the concept of an antibody-drug conjugate and the early work to do the initial chemistry. We contributed 30 years of research, the targeted medicine, and our expertise in antibody-engineering and in medicinal chemistry. By partnering early, we were able to create a brand new approach to treatment.

A wedding is not the same as a marriage

We close between 10 and 20 deals a year. And because we work with others in so many different ways, there is a lot of creativity in how we structure them. When we formalize a deal it’s a great thing. We celebrate because it’s good when like-minded people come together in the interest of science and patients.

After the celebration is done, the marriage begins. And like a marriage our relationships evolve, based on about what is in our best interests, what is the best interest of our partner. The most important consideration is what is in the best interest of patients. We look and hope to be sought by people who believe in our company’s mission to help people with serious or life-threatening conditions.

Working towards a common goal

In the end, the patient is the one who benefits from collaborations. Everything we do is concentrated on how we can better the lives of people in need. The best way to do that is to help each other create and execute new ideas.

Biotechnology is a community of scientists and business people, much like a beehive, where everyone works together towards a common goal. It’s a partnered world out there – in nature and at Genentech. `QED Mark`


Tags:

  • Partnering

Read More Stories


Understanding CLL

Genentech

Chronic lymphocytic leukemia, or CLL, is a slow-growing cancer of the blood and bone marrow. It is the most common type of adult leukemia.

A Bispecific Revolution

Genentech

A new generation of therapeutic antibodies does nature one better.

Planning for the Future

Genentech

New research into advanced bladder cancer is giving people hope for the future. This is Peter’s story.

Feedback?

Tell us what you think about our company, products, or website.

“
The scientist is not a person who gives the right answers, he’s one who asks the right questions.
” – Claude Lévi-Strauss
  • Now Hiring
  • Work Here
  • Find A Job
  • University & Early Career
  • Professional Areas
  • For Scientists
  • Our Scientists
  • Publications
  • Oncology
  • Immunology
  • Neuroscience
  • Metabolism
  • Infectious Disease
  • Ophthalmology
  • For Patients
  • Our Medicines
  • Financial Support
  • Medicine Information Support
  • Investigational Medicines
  • Genentech Patient Foundation
  • Disease Education
  • Advancing Inclusive Research
  • For Medical Professionals
  • Our Medicines
  • Our Pipeline
  • Medical Resources
  • Sunshine Act Compliance
  • Product Security
  • For Partners
  • Our Approach
  • Our Relationship with Roche
  • Partner With Us
  • Our Stories
  • For Media
  • News Features
  • Press Releases
  • Statements
  • Company Information
  • Sign Up For News Alerts
  • For Good
  • Local Initiatives
  • Giving
  • Diversity & Inclusion
  • Environmental Sustainability
  • About Us
  • Leadership
  • Awards & Recognition
  • Investors
  • Suppliers
  • CA Transparency in Supply
  • Compliance Overview
  • Contact Us
  • Call Us
  • Email Us
  • Connect With Us
  • Visit us
  • Submit a Medical Inquiry
  • Submit a Media Inquiry
Connect with us
Privacy Policy  |  Terms & Conditions
Genentech, Inc. © 2019